Ampio announces FDA acceptance of POPE questionnaire Ampio Pharmaceuticals announced FDA acceptance of its POPE questionnaire, a modification of the Premature Ejaculation Profile questionnaire that was used in the two successful Zertane Phase 3 clinical trials completed in Europe.
News For AMPE From The Last 14 Days
Check below for free stories on AMPE the last two weeks.
